GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (LTS:0J8Z) » Definitions » Cyclically Adjusted PS Ratio

Illumina (LTS:0J8Z) Cyclically Adjusted PS Ratio : 5.31 (As of Dec. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Illumina Cyclically Adjusted PS Ratio?

As of today (2024-12-16), Illumina's current share price is $142.5421. Illumina's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $26.84. Illumina's Cyclically Adjusted PS Ratio for today is 5.31.

The historical rank and industry rank for Illumina's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0J8Z' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.65   Med: 19.35   Max: 32.69
Current: 5.34

During the past years, Illumina's highest Cyclically Adjusted PS Ratio was 32.69. The lowest was 3.65. And the median was 19.35.

LTS:0J8Z's Cyclically Adjusted PS Ratio is ranked worse than
71.31% of 122 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.625 vs LTS:0J8Z: 5.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Illumina's adjusted revenue per share data for the three months ended in Sep. 2024 was $6.750. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $26.84 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Illumina's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted PS Ratio Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.45 21.55 18.50 8.51 5.33

Illumina Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 5.33 5.10 3.92 4.84

Competitive Comparison of Illumina's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted PS Ratio falls into.



Illumina Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Illumina's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=142.5421/26.84
=5.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Illumina's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=6.75/133.0289*133.0289
=6.750

Current CPI (Sep. 2024) = 133.0289.

Illumina Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 3.447 99.070 4.629
201503 3.622 99.621 4.837
201506 3.621 100.684 4.784
201509 3.677 100.392 4.872
201512 3.980 99.792 5.306
201603 3.865 100.470 5.117
201606 4.054 101.688 5.303
201609 4.101 101.861 5.356
201612 4.182 101.863 5.462
201703 4.068 102.862 5.261
201706 4.503 103.349 5.796
201709 4.824 104.136 6.162
201712 5.250 104.011 6.715
201803 5.284 105.290 6.676
201806 5.608 106.317 7.017
201809 5.725 106.507 7.151
201812 5.704 105.998 7.159
201903 5.678 107.251 7.043
201906 5.624 108.070 6.923
201909 6.128 108.329 7.525
201912 6.389 108.420 7.839
202003 5.804 108.902 7.090
202006 4.277 108.767 5.231
202009 5.365 109.815 6.499
202012 6.439 109.897 7.794
202103 7.435 111.754 8.850
202106 7.660 114.631 8.889
202109 7.242 115.734 8.324
202112 7.637 117.630 8.637
202203 7.692 121.301 8.436
202206 7.401 125.017 7.875
202209 7.102 125.227 7.544
202212 6.898 125.222 7.328
202303 6.880 127.348 7.187
202306 7.443 128.729 7.692
202309 7.082 129.860 7.255
202312 7.101 129.419 7.299
202403 6.767 131.776 6.831
202406 6.994 132.554 7.019
202409 6.750 133.029 6.750

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (LTS:0J8Z) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Illumina Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Headlines

No Headlines